MTVA MetaVia Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1638287 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY3.2%
TTM EPS YoY93.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-359.0%
ROA-129.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets74.8%
Debt / equity0.00x
Current ratio1.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.06x
Accruals ratio7.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $6.80M | $21.55M | $9.16M | $2.78M | $6.55M |
| SG&A expense | $6.91M | $7.26M | $6.73M | $8.64M | $8.75M |
| Operating income | -$13.71M | -$28.81M | -$15.89M | -$19.63M | -$15.30M |
| Pretax income | -$12.97M | -$27.59M | -$12.47M | -$13.97M | -$15.28M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.97M | -$27.59M | -$12.47M | -$13.97M | -$15.28M |
| EBITDA | -$13.69M | -$28.79M | -$15.88M | -$19.61M | -$15.25M |
| EPS (basic) | -7.35 | -39.13 | -2.46 | -43.42 | -19.81 |
| EPS (diluted) | -7.35 | -39.13 | -2.46 | -43.42 | -19.81 |
| Weighted avg. shares (diluted) | 1.77M | 705,193 | 5.07M | 321,703 | 771,422 |
| Banking | |||||
| Net interest income | $510,000 | $920,000 | $461,000 | — | $14,000 |
| Balance sheet | |||||
| Cash & equivalents | $10.28M | $16.02M | $22.43M | $33.36M | $16.39M |
| Current assets | $10.88M | $16.07M | $22.51M | $33.53M | $16.58M |
| PP&E, net | $17,000 | $34,000 | $46,000 | $2,000 | $110,000 |
| Total assets | $11.12M | $16.26M | $22.78M | $33.53M | $16.80M |
| Current liabilities | $5.65M | $8.27M | $5.96M | $11.78M | $2.16M |
| Total liabilities | $5.79M | $8.33M | $6.10M | $11.78M | $2.20M |
| Shareholders' equity | $5.33M | $7.93M | $16.68M | $21.75M | $14.60M |
| Shares outstanding | 2.31M | 785,194 | 4.91M | 3.18M | 888,693 |
| Cash flow statement | |||||
| Operating cash flow | -$15.70M | -$24.71M | -$10.80M | -$11.71M | -$15.13M |
| Capital expenditure | $2,000 | $8,000 | $50,000 | — | $3,000 |
| Free cash flow | -$15.70M | -$24.72M | -$10.85M | — | -$15.14M |
| Investing cash flow | -$2,000 | -$8,000 | -$50,000 | $8,000 | -$586,000 |
| Financing cash flow | $9.96M | $18.30M | -$80,000 | $28.68M | $22.03M |
| Depreciation & amortization | $19,000 | $20,000 | $6,000 | $20,000 | $48,000 |
| Stock-based compensation | $411,000 | $538,000 | $222,000 | $854,000 | $662,000 |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.